European growth debt fund Claret Capital Partners raises €575M, with a third earmarked for biotech, medtech and diagnostics ...
Zymeworks is set to put Theravance Biopharma out of its misery, announcing on Monday that it will buy the biotech for $929 million upfront in cash. In March, Theravance said it was ...
After Novo Nordisk and AstraZeneca, Novartis is the third big pharma to suffer a major cardiovascular outcomes trial failure in the past two months.
Lindus Therapeutics sheds its CRO business, rebrands from Lindus Health and pivots to in-licensing external drug assets, CEO ...
Alumis' lupus drug misses its Phase 2b goal, sending shares down over 50%, but a high-IFNGS subgroup shows a path toward ...
GSK to spend $110M upfront licensing Hutchmed's KRAS-EGFR cancer drug HMPL-A830, up to $1.295B total, pending antitrust ...
Eli Lilly acquires Merida Biosciences for up to $2.875B, gaining MER511 for thyroid eye disease/Graves' disease and MER769 ...
Metriport raises $26M Series A led by Matrix to help doctors retrieve and prioritize patient data from across health systems.
ARCH Venture Partners is targeting $3B for its 14th fund, per an SEC filing, matching the size of the fund it disclosed in ...
CEPI has funneled $100M across five-plus Ebola vaccine candidates, including Moderna and Hilleman Labs, but says it still needs $128M to keep pace.
Lilly's 13 acquisitions in 2026, worth about $32B, are recycling cash back to at least 50 biotech venture investors.
Novartis halts CAR-T trials after three patient deaths from an immune overreaction; Bristol Myers pauses zola-cel enrollment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results